Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-01-06
1999-10-26
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514689, 514563, A61K 3712
Patent
active
059730048
ABSTRACT:
A combination can be of L-carnitine and acetyl-L-carnitine, preferably with pantothenic acid or ubiquinone, is administered orally or as a parenteral injection in domesticated animals, especially pet animals, and humans for prevention or treatment of syndromes or diseases arising from dysfunctional energy metabolism. Syndromes involving skeletal and cardiac muscle benefited from L-carnitine, and syndromes related to the central nervous system improved with acetyl-L-carnitine, are effectively treated. The cofactors L-carnitine and acetyl-L-carnitine do not substitute metabolically for each other, and the effects of the combination are found to be synergistic.
REFERENCES:
patent: 4599232 (1986-07-01), Bertelli
patent: 5576384 (1996-11-01), Nolken et al.
patent: 5889055 (1999-03-01), Howard
Luft: "The development of mitochondrial medicine," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 8731-8738, Sep. 1994.
Singh et al: "Mitochondroial Genome Mutations and Kidney Disease," American Journal of Kidney Diseases, vol. 28, No. 1 (Jul.), 1996; pp. 140-146.
Shishido et al: "Cerebral oxygen and glucose metabolism and blood flow in mitochondrial encephalomyopathy; a pet study," Neuroradiology (1996) 38: pp. 102-107.
Pons et al: "Primary and Secondary Carnitine Deficiency Syndromes," Journal of child Neurology, vol. 10, Supplement No. 2, Nov. 1995, pp. 2S9-2S24.
Castorina et al: "Acetyl-L-Carnitine Affects Aged Brain Receptorial System in Rodents," Life Sciences, vol. 54, No. 17, pp. 1205-1214, 1994.
Carta et al: "Acetyl-L-Carnitine and Alzheimer's Disease: Pharmacological Considerations Beyond the Cholinergic Sphere, " New York Academy of Science, pp. 324-326.
Aureli et al: "Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by .sup.31 P and .sup.1 H NMR spectroscopy," Brain Research, 326 (1990), pp. 108-112.
Stanley: "Carnitine Disorders," Advances in Pediatrics, vol. 42, 1995, pp. 209-242.
Shoubridge: "Mitochondrial DNA Diseases: Histological and Cellular Studies," Journal of Bioenergetics and Biomembranes, vol. 26, No. 3, 1994, pp. 301-310.
Zeviani et al: "Mitochondrial myopathies," Current Opinion in Rheumatology 1994, pp. 559-567.
Sisson et al: "Myocardial Diseases," Textbook of Veterinary Internal Medicine, Chapter 96, pp. 995-1005.
Kittleson et al: "Results of the Multicenter Spaniel Trial (MUST): Taurine- and Carnitine-Responsive Dilated Cardiomyopathy in American Cocker Spaniels With Decreased Plasma Taurine Concentration," Journal of Veterinary Internal Medicine, vol. 11, No. 4 (Jul.-Aug.), 1997, pp. 204-211.
Bremer: "Carnitine--Functions," Physiological Reviews, vol. 63, No. 4, Oct. 1983, pp. 1420-1456.
LandOfFree
L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-765275